A meta-analysis of the Zilongjin tablets for non-small cell lung cancer and its network pharmacology of action against NSCLC and COVID-19

Frontiers in Medicine

Medicine

Jing Gao¹  Pengcheng Hu²  Yanjie Yang³  Yichao Zhang⁴  Wuxia Yang⁵  Xiaoqing Xu⁵ 

[1] Clinical Laboratory, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China;National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China;Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;Shunde Hospital of Southern Medical University, Foshan, China;The Graduate School, Qinghai University, Xining, China;The Graduate School, Tianjin Medical University, Tianjin, China;

关键词: Zilongjin tablets;    non-small cell lung cancer (NSCLC);    COVID-19;    traditional Chinese medicine;    meta-analysis;    network pharmacology;   

DOI  :  10.3389/fmed.2023.1080121

 received in 2022-10-25, accepted in 2023-07-05,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveTo objectively evaluate the efficacy of the Zilongjin tablets in non-small cell lung cancer (NSCLC) and to explore its potential mechanism of action against NSCLC and COVID-19 based on network pharmacology.MethodsThe database was searched for randomized controlled trials (RCTs) of the Zilongjin tablets for NSCLC published up to 22 August 2022. The quality of included trials was assessed using Cochrane standard guidelines, and a meta-analysis was performed using Rev Man 5.3. Gene targets for intersections of NSCLC and COVID-19 (the NC) and drugs were obtained from the TCMSP database, HERB database, GeneCards database, and the NCBI database for network pharmacology research.ResultsMeta-analysis included 14 articles with 2,430 patients. The meta-analysis showed that the Zilongjin tablets combined with conventional chemotherapy were significantly more effective than chemotherapy alone in the treatment of NSCLC. A total of 29 drug-disease intersecting targets were identified in the network pharmacology. The “ingredient-target-pathway” diagram component-target-pathway network contained 119 nodes and 429 edges, with the majority of targets associated with inflammatory responses.ConclusionThe efficacy and quality of life of the Zilongjin tablets combined conventional chemotherapy for NSCLC were significantly better than chemotherapy alone, alleviating various adverse effects. At the same time, the Zilongjin tablets may modulate the inflammatory response to alleviate NSCLC and COVID-19.

【 授权许可】

Unknown   
Copyright © 2023 Yang, Zhang, Gao, Hu, Yang and Xu.